Komori
Earnings6323RORZE CORPORATIONMachinery

Summary of Consolidated Financial Results for the Three Months Ended February 2026 [Japanese GAAP]

台湾向けの需要増で売上高は増加した一方、営業利益は小幅に減少し、為替の影響などから経常利益と最終利益は大幅に減少した。通期業績予想と年間配当予想は据え置かれている。

Worth reading
52Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
12.9
% (year-on-year change in revenue)
Wording
Conditional
How definitive the wording is.

Results for this period

First quarter2025年3月1日〜2025年5月31日ConsolidatedJapanese GAAP
Net Sales33,061¥ millionYear on year +12.9%Progress 25.8%
Operating profit8,441¥ millionYear on year -3.5%Progress 27.8%
Ordinary income7,241¥ millionYear on year -36.3%Progress 23.6%
Net income attributable to owners of the parent5,263¥ millionYear on year -40.0%Progress 22.4%

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.

Net income per share29円91銭
Financial position at period-end
Total assets177,092¥ million
of which net assets 123,376 ¥ millionEquity ratio 64.1%vs. prior year-end +1.3pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Segment revenueSemiconductor and FPD Equipment Business ¥32,950 million (YoY +13.1%), Life Sciences Business ¥110 million (YoY -27.7%)
Segment profitSemiconductor and FPD Equipment Business ¥8,786 million (YoY -2.0%), Life Sciences Business ¥-110 million
Regional sales¥2,305 million, ¥9,575 million, ¥8,561 million, ¥1,603 million, ¥8,204 million, ¥2,809 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥128,190 million (YoY +3.0%)
Operating profit¥30,345 million (YoY -5.2%)
Ordinary income¥30,618 million (YoY -13.6%)
Net income¥23,499 million (YoY -0.6%)
Revision to Earnings ForecastNo
Annual Dividend Forecast¥17 → ¥17(0.0%)
Factors Behind Changes in Business Performance

主に台湾向けで需要が増加した結果、売上高が増加した。経常利益は為替の影響も受けた。

Disclosure regarding the going concern assumption

Not applicable.

Change in accounting policy
基準改正に伴う変更 Yesそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 / Name of newly added company Not disclosed / Excluded 0 / Excluded Company Name Not disclosed
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥12 million / Extraordinary loss Loss on sale of fixed assets ¥0 million, Loss on Disposal of Fixed Assets ¥0 million
Depreciation and amortization¥759 million
Orders received and order backlogOrders received ¥24,220 million / Order backlog ¥53,300 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable No / Subject person Not disclosed
Issued Shares at Period-End176,400,000 Shares
Treasury Shares at Period-End1,355,760 Shares
Results for this period
ItemDetails
Fiscal Period ClassificationFirst quarter
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedConsolidated
Period Covered2025年3月1日〜2025年5月31日
Net Sales¥33,061 million (YoY +12.9%)
Operating profit¥8,441 million (YoY -3.5%)
Ordinary income¥7,241 million (YoY -36.3%)
Profit attributable to owners of the parent¥5,263 million (YoY -40.0%)
Net income per share29円91銭
Equity ratioEnd of the current fiscal period 64.1 / End of previous period 62.8
Total assets¥177,092 million
Net assets¥123,376 million
Full-year earnings forecastNet Sales ¥128,190 million (YoY +3.0%) / Operating profit ¥30,345 million (YoY -5.2%) / Ordinary income ¥30,618 million (YoY -13.6%) / Net income ¥23,499 million (YoY -0.6%)
Revision to Earnings ForecastNo
Annual Dividend Forecast¥17 → ¥17(0.0%)
Segment revenueSemiconductor and FPD Equipment Business ¥32,950 million (YoY +13.1%), Life Sciences Business ¥110 million (YoY -27.7%)
Segment profitSemiconductor and FPD Equipment Business ¥8,786 million (YoY -2.0%), Life Sciences Business ¥-110 million
Regional sales¥2,305 million, ¥9,575 million, ¥8,561 million, ¥1,603 million, ¥8,204 million, ¥2,809 million
Orders received and order backlogOrders received ¥24,220 million / Order backlog ¥53,300 million
Depreciation and amortization¥759 million
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥12 million / Extraordinary loss Loss on sale of fixed assets ¥0 million, Loss on Disposal of Fixed Assets ¥0 million
Disclosure regarding the going concern assumptionNot applicable.
Change in accounting policyChanges due to revisions to standards Yes / Other changes No / Change in accounting estimate No / Restatement No
Changes in the scope of consolidationNew 0 / Name of newly added company Not disclosed / Excluded 0 / Excluded Company Name Not disclosed
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable No / Subject person Not disclosed
Issued Shares at Period-End176,400,000 Shares
Treasury Shares at Period-End1,355,760 Shares
Factors Behind Changes in Business Performance主に台湾向けで需要が増加した結果、売上高が増加した。経常利益は為替の影響も受けた。
Items this document does not state (9)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodPayout ratioShareholder Return PolicyImpairment lossMaterial subsequent events

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

主に台湾向けで需要が増加した結果、売上高が増加した。経常利益は為替の影響も受けた。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Summary of Consolidated Financial Results for the Three Months Ended February 2026 [Japanese GAAP] | RORZE CORPORATION (6323) timely disclosure | Komori